EGFR and non-small cell lung carcinoma: Although we found no significant interstudy heterogeneity in all direct comprisons (up to 27.9% of the I2 value), the conclusion for indirect comparisons may be further confirmed by randomized controlled trials.To the best of our knowledge, this is the first meta-analysis comparing immune checkpoint inhibitor, EGFR-TKI and chemotherapy for advanced NSCLC patients with WT EGFR tumors in second- or third-line therapy.